Press release

Release
11.09.2018

Positive results from Phase I/II clinical study on LpD64

Download
Release
30.08.2018

Appointment of Pascal SIRVENT to the Board of Directors of VALBIOTIS

Download
Release
17.07.2018

Half-year report of the liquidity contract – July 2018 (in French)

Download
Release
10.07.2018

Positive results from first Phase I/II clinical study of VAL-070 in hypercholesterolemia

Download
Release
19.06.2018

Cécile Merle appointed to the position of Quality Assurance Director

Download
Release
07.06.2018

VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIA

Download
Release
15.05.2018

The clinical development of VALEDIA® initiated in the USA

Download
Release
14.05.2018

Evolution in the composition of the board of Directors (in French)

Download
Release
03.04.2018

Annual results 2017

Download